Form 4: Veracyte CFO Executes Planned Stock Sales in June

Veracyte Chief Financial Officer Rebecca Chambers sold 3,561 shares and had 3,693 shares withheld for taxes under a pre-arranged trading plan.

Summary

• Chief Financial Officer Rebecca Chambers engaged in multiple transactions involving Veracyte (VCYT) common stock between June 2 and June 4, 2026.
• On June 2, 2026, 3,693 shares were withheld by the company at a price of $47.80 per share to cover tax obligations resulting from the vesting of restricted stock units.
• On June 4, 2026, the CFO sold 1,600 shares at a weighted average price of $49.2836 and an additional 1,961 shares at a weighted average price of $50.0913.
• The sales on June 4 were executed under a Rule 10b5-1 trading plan, which was previously adopted on August 21, 2025.
• Following these transactions, Rebecca Chambers directly owns 173,280 shares of Veracyte common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; it is a routine administrative filing for executive compensation management with no impact on company fundamentals.

Positives

• The CFO maintains a substantial direct ownership stake of 173,280 shares, aligning her interests with shareholders.
• Sales were conducted under a Rule 10b5-1 plan, providing transparency and indicating they were not based on immediate non-public information.
• The stock was sold at prices ranging up to $50.40, showing recent price strength compared to the tax withholding price of $47.80.

Negatives

• The disposal of 7,254 total shares (including tax withholdings) reduces the executive's total exposure to the company's equity.
• Insider selling, even when planned, can sometimes be interpreted by the market as a lack of aggressive bullishness from top management.

Risks

• Market volatility may impact the execution prices of future sales under the existing 10b5-1 plan.
• Concentration of executive wealth in company stock remains high, which could lead to further periodic liquidations for diversification.

Future Outlook

The use of a Rule 10b5-1 plan suggests that the reporting person may have additional scheduled transactions in the future to manage equity compensation and personal liquidity.

Management Comments

• The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.

Industry Context

StockSavvy.ai notes that routine insider sales under 10b5-1 plans are common among executives in the diagnostics and biotechnology sectors, often used to manage the tax consequences of vesting equity awards without signaling a change in corporate strategy.

Comparison to Industry Standards

• The volume of shares sold is relatively small compared to the total holding, which is consistent with standard executive liquidity management seen at peers like Exact Sciences or Natera.
• Adoption of 10b5-1 plans several months in advance of trading is a best-practice governance standard for U.S. listed companies.

Related Party Transactions

• The reporting person is the Chief Financial Officer of the issuer, and the transactions involve the issuer's equity securities.

Stakeholder Impact

• Shareholders should see this as a routine liquidity event for an executive rather than a strategic shift.
• The company's treasury is impacted by the withholding of shares to settle tax debts on behalf of the executive.

Next Steps

• Monitor future Form 4 filings for continued activity under the August 2025 trading plan.

Key Dates

Recommendation

The filing represents routine insider activity under a pre-set plan and does not provide new information regarding the company's operational performance or financial health that would warrant a change in investment thesis.

Keywords

Veracyte, VCYT, Insider Trading, CFO, Rebecca Chambers, Rule 10b5-1, Common Stock, Stock Vesting